동인화학

비상장계속사업자

DONGINCHEMICAL CO.,LTD.

김선경

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

동인화학

Business Reg. No. 3078111426 · CEO 김선경

I.Investment Overview

Target동인화학 (3078111426)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명동인화학
영문명DONGINCHEMICAL CO.,LTD.
대표자김선경
사업자등록번호3078111426
법인등록번호1647110005014
설립일1997.12.16
종업원수21명

V.Workforce

21

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW106.12021154.92022186.62023176.42024236.32025
영업이익100M KRW8.4202124.8202226.920233.520244.72025
순이익100M KRW6.4202119.9202220.620232.220249.52025
Item20252024202320222021
자산총계208.2억원201.4억원193.4억원172.2억원141.9억원
부채총계108.3억원110.9억원105.2억원104.6억원94.1억원
자본총계99.9억원90.4억원88.2억원67.6억원47.8억원
매출액236.3억원176.4억원186.6억원154.9억원106.1억원
영업이익4.7억원3.5억원26.9억원24.8억원8.4억원
순이익9.5억원2.2억원20.6억원19.9억원6.4억원

VII.Financial Ratios

FY2025 basis

1.98%

영업이익률

4%

순이익률

4.55%

ROA

9.47%

ROE

108.38%

부채비율

47.99%

자기자본비율

VIII.R&D Activity

Fields 생명과학 > 산업바이오

Keywords 바이오, 트리스, 광학이성체, 항히스타민제, 비대칭합성

YearProjectsPapersPatents
2026100
2025100
2024100
2012002
2011100
2010100

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

동인화학 투심보고서 | Alpha Lenz